{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:22:11Z","timestamp":1783506131637,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bmcl.2022.128870","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T20:18:56Z","timestamp":1656361136000},"page":"128870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Synthesis and biological evaluation of niclosamide PROTACs"],"prefix":"10.1016","volume":"72","author":[{"given":"Erick","family":"Munoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahamed","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esveidy","family":"Oceguera Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"72","key":"10.1016\/j.bmcl.2022.128870_b0005","first-page":"7","article-title":"Cancer statistics, CA: Cancer","volume":"2022","author":"Siegel","year":"2022","journal-title":"J. Clin"},{"key":"10.1016\/j.bmcl.2022.128870_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: Structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.bmcl.2022.128870_b0015","first-page":"3","article-title":"Androgen receptor structure, function and biology: From bench to bedside","volume":"37","author":"Davey","year":"2016","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.bmcl.2022.128870_b0020","doi-asserted-by":"crossref","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 168:9\u201312.","DOI":"10.1016\/S0022-5347(05)64820-3"},{"key":"10.1016\/j.bmcl.2022.128870_b0025","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2022.128870_b0030","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2022.128870_b0035","first-page":"1235","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"Yearb Paediatr Endocrinol"},{"key":"10.1016\/j.bmcl.2022.128870_b0040","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3390\/molecules25102448","article-title":"Second-generation androgen receptor antagonists as hormonal therapeutics for three forms of prostate cancer","volume":"25","author":"Rajaram","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bmcl.2022.128870_b0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2022.128870_b0050","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to Enzalutamide and Abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2022.128870_b0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1210\/me.2014-1315","article-title":"Minireview: Tipping the balance: Ligand-independent activation of steroid receptors","volume":"29","author":"Bennesch","year":"2015","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.bmcl.2022.128870_b0060","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1158\/1078-0432.CCR-13-3296","article-title":"Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer","volume":"20","author":"Liu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128870_b0065","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1021\/ml100146z","article-title":"Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway","volume":"1","author":"Ren","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128870_b0070","doi-asserted-by":"crossref","first-page":"e0198389","DOI":"10.1371\/journal.pone.0198389","article-title":"A Phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer","volume":"13","author":"Schweizer","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmcl.2022.128870_b0075","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2022.128870_b0080","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1042\/BCJ20160762","article-title":"Chemical approaches to targeted protein degradation through modulation of the ubiquitin\u2013proteasome pathway","volume":"474","author":"Collins","year":"2017","journal-title":"Biochem J"},{"key":"10.1016\/j.bmcl.2022.128870_b0085","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s42003-018-0105-8","article-title":"Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms Enzalutamide in cellular models of prostate cancer drug resistance","volume":"1","author":"Salami","year":"2018","journal-title":"Commun Biol"},{"key":"10.1016\/j.bmcl.2022.128870_b0090","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.jmedchem.8b01631","article-title":"Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer","volume":"62","author":"Han","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128870_b0095","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the role of linker design in proteolysis targeting chimeras","volume":"64","author":"Bemis","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128870_b0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: Beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell Signal"},{"key":"10.1016\/j.bmcl.2022.128870_b0105","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/pros.23015","article-title":"Niclosamide suppress cell migration and invasion in enzalutamide resistant prostate cancer cells via STAT3-AR axis inhibition","volume":"75","author":"Liu","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.bmcl.2022.128870_b0110","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) \u2014 Past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.bmcl.2022.128870_b0115","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/med.21548","article-title":"Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-ligand binding domain","volume":"39","author":"Elshan","year":"2019","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmcl.2022.128870_b0120","doi-asserted-by":"crossref","first-page":"38087","DOI":"10.1074\/jbc.M203313200","article-title":"Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells","volume":"277","author":"Ueda","year":"2002","journal-title":"J Biol Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:46:05Z","timestamp":1760773565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22003468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":24,"alternative-id":["S0960894X22003468"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128870","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological evaluation of niclosamide PROTACs","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128870"}}